EcoDrugPlus

Potassium Inwardly Rectifying Channel Subfamily J Member 2

Ensembl ID : ENSNGAG00000008136
Gene Symbol: KCNJ2
3 Cross references
277 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 3

Ensembl ID : ENSNGAG00000002124
Gene Symbol: KCNJ3
3 Cross references
219 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 5

Ensembl ID : ENSNGAG00000002517
Gene Symbol: KCNJ5
3 Cross references
205 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 2

Ensembl ID : ENSNGAG00000015617
Gene Symbol: KCNK2
3 Cross references
280 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 3

Ensembl ID : ENSNGAG00000018512
Gene Symbol: KCNK3
3 Cross references
203 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 9

Ensembl ID : ENSNGAG00000015255
Gene Symbol: KCNK9
3 Cross references
211 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily A Member 5

Ensembl ID : ENSNGAG00000001282
Gene Symbol: KCNA5
3 Cross references
169 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSNGAG00000011906
Gene Symbol: KCND3
3 Cross references
259 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily H Member 2

Ensembl ID : ENSNGAG00000021118
Gene Symbol: KCNH2
3 Cross references
252 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSNGAG00000020074
Gene Symbol: KCNQ2
3 Cross references
248 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSNGAG00000000230
Gene Symbol: KCNQ3
3 Cross references
191 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSNGAG00000018452
Gene Symbol: KCNQ5
3 Cross references
278 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).